Company* (Symbol)

Type of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)

Amarillo Biosciences Inc.

Conversion of debt into equity



Hyashibara Biochemical Laboratories converted 2 loans totaling $2.6M (plus $0.24M in interest) into equity, receiving 0.95M shares at $3 per share; conversion raises HBL's stake in Amarillo from 23% to 34.3% (4/5)

Corixa Corp.

Equity-based credit line



Castle Gate LLC will provide up to $50M of equity capital under a 2-year credit line, with an initial draw of $12.5M (12,500 shares of Series A preferred stock at $1,000 per share, convertible at fixed exchange of $8.50 per share); conversion rates on future draws will be based upon average closing price of Corixa stock before and after the draw date; dividends on on the convertible stock will accrue at 5% per year, payable in stock or cash at Corixa's option (4/9)

Cypress Bioscience Inc.

Exercise of publicly traded warrants



Approximately 2.6M of 2.8M outstanding publicly traded warrants have been exercised, with proceeds to Cypress of $5.2M; warrants were called for redemption on 3/17; those not exercised by 4/19 were redeemed at $0.10 per warrant on 4/19 (4/21)

Matritech Inc.

Private placement



Matritech completed $4M private placement of 3.1M shares to Grethe R. Bruckner, A.B. Siemer and Zero Stage Capital VI LP (4/07)

Neurobiological Technologies Inc. (OTC BB:NTII)

Private financing



Existing and new investors participated in the financing, which was managed by the company; further details ND (4/19)

Organogenesis Inc.

Private placement of convertible debentures



Organogenesis raised $20M through private placement of $20M worth of convertible debentures at a fixed price of $15 per share; the debentures have attached 0.4M 5-year warrants at $22.50 per share (4/1)


Convertible debt financing



SangStat completed convertible debt Medical Corp. financing of $10M in aggregate principal amount of securities with an undisclosed financial institution; the securities have a maturity of 5 years and are convertible at any time prior to maturity into approximately 0.5M shares of common stock, representing a conversion price of approximately $20 per share (4/5)

Vion Pharmaceuticals Inc.

Direct private placement



Vion raised $4M through the sale of 0.89 common shares to Elliott Associates LP, Westgate International LP, United Equities Commodities Co., Wechsler and Co. Inc., Kleinwort Benson Ltd., and Winchester Capital Healthcare Partners LLC (4/23)

TOTAL: $97.1

*Unless otherwise noted, stock symbols for biotechnology companies appear on pp. 11-12.
ND = Not disclosed, reported and/or available; S = Shares
The financings in this chart include loans, bridge financings and other interim measures as well as sales of business units, debt offerings, rights offerings, exercises of warrants, institutional offerings of registered stock and standard private placements.